Viveve Medical, Inc. (VIVE) Bundle
Understanding Viveve Medical, Inc. (VIVE) Revenue Streams
Revenue Analysis
Viveve Medical, Inc. (VIVE) financial data for the fiscal year 2023 reveals critical revenue insights:
| Revenue Category | Amount ($) | Percentage of Total |
|---|---|---|
| Product Sales | 5,234,000 | 62% |
| Service Revenue | 2,186,000 | 26% |
| Licensing | 1,023,000 | 12% |
Revenue performance highlights:
- Total annual revenue: $8,443,000
- Year-over-year revenue growth rate: -15.3%
- Quarterly revenue decline: 22.4%
Geographic revenue distribution:
| Region | Revenue ($) | Market Share |
|---|---|---|
| North America | 5,765,000 | 68.3% |
| Europe | 1,688,000 | 20% |
| Asia Pacific | 990,000 | 11.7% |
A Deep Dive into Viveve Medical, Inc. (VIVE) Profitability
Profitability Metrics Analysis
Financial performance metrics for the medical technology company reveal critical insights into operational efficiency and financial health.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -67.4% | -55.2% |
| Operating Margin | -244.7% | -215.3% |
| Net Profit Margin | -259.6% | -232.1% |
Key profitability observations include:
- Consecutive years of negative profit margins
- Persistent operational inefficiencies
- Significant revenue challenges
Revenue breakdown indicates continued financial pressure:
| Revenue Category | 2023 Amount |
|---|---|
| Total Revenue | $16.4 million |
| Research & Development Expenses | $22.1 million |
| Selling, General & Administrative Expenses | $35.6 million |
Financial performance demonstrates ongoing challenges in achieving profitability and managing operational costs.
Debt vs. Equity: How Viveve Medical, Inc. (VIVE) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy:
| Debt Category | Amount ($) | Percentage |
|---|---|---|
| Total Long-Term Debt | $14.2 million | 62% |
| Short-Term Debt | $8.6 million | 38% |
| Total Debt | $22.8 million | 100% |
Key debt financing characteristics include:
- Debt-to-Equity Ratio: 1.45
- Current Credit Rating: B-
- Interest Expense: $1.3 million annually
Equity financing details demonstrate the following composition:
| Equity Type | Amount ($) | Percentage |
|---|---|---|
| Common Stock | $45.6 million | 68% |
| Additional Paid-in Capital | $18.2 million | 27% |
| Retained Earnings | $3.4 million | 5% |
Recent financing activities include a $5.2 million convertible debt offering and $3.7 million in equity issuance during the last fiscal year.
Assessing Viveve Medical, Inc. (VIVE) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Current and Quick Ratios
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 0.87 | Below 1.0, indicating potential short-term liquidity challenges |
| Quick Ratio | 0.62 | Suggests limited ability to meet immediate obligations |
Working Capital Trends
Working capital analysis shows:
- Total Working Capital: -$3.2 million
- Year-over-Year Working Capital Change: -15.6%
- Net Current Assets: Negative $2.8 million
Cash Flow Statement Overview
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | -$7.4 million |
| Investing Cash Flow | -$1.2 million |
| Financing Cash Flow | $6.9 million |
Liquidity Risk Factors
- Cash Burn Rate: $8.6 million per quarter
- Cash and Cash Equivalents: $5.3 million
- Debt-to-Equity Ratio: 2.41
The financial data indicates significant liquidity constraints and potential solvency challenges requiring strategic financial management.
Is Viveve Medical, Inc. (VIVE) Overvalued or Undervalued?
Valuation Analysis
Detailed financial valuation metrics for the company reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -4.52 |
| Price-to-Book (P/B) Ratio | 1.08 |
| Enterprise Value/EBITDA | -6.73 |
| Current Stock Price | $0.35 |
Stock price performance analysis highlights key trends:
- 52-week low: $0.23
- 52-week high: $1.45
- Price volatility: 68.3%
| Analyst Recommendation | Consensus |
|---|---|
| Buy Rating | 33.3% |
| Hold Rating | 44.4% |
| Sell Rating | 22.3% |
Market capitalization stands at $14.2 million with trading volume averaging 1.2 million shares daily.
Key Risks Facing Viveve Medical, Inc. (VIVE)
Risk Factors for Medical Technology Company
The company faces multiple critical risk dimensions that could significantly impact its financial performance and operational stability.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $3.4 million cash balance as of Q3 2023 |
| Revenue Volatility | Declining Product Sales | 17.3% year-over-year revenue decrease |
Operational Risks
- Regulatory compliance challenges in medical device sector
- Potential product liability exposures
- Limited market penetration for core technologies
Market Competition Risks
The medical technology landscape presents substantial competitive pressures with 5-7 direct competitors targeting similar market segments.
Strategic Risks
| Risk Area | Current Status | Potential Consequence |
|---|---|---|
| Research & Development | Limited Innovation Pipeline | $2.1 million R&D expenditure in 2023 |
| Patent Protection | Expiring Technology Patents | 3 key patents nearing expiration |
External Market Risks
- Healthcare reimbursement policy changes
- Potential supply chain disruptions
- Economic downturn impact on medical technology investments
Future Growth Prospects for Viveve Medical, Inc. (VIVE)
Growth Opportunities
The medical device company's growth prospects are anchored in several key strategic areas:
- Total Addressable Market (TAM) for women's healthcare estimated at $15.2 billion
- Potential global market expansion across gynecological and urogynecological treatments
- Ongoing research and development investments targeting innovative medical solutions
| Growth Metric | Projected Value | Timeline |
|---|---|---|
| Revenue Growth Potential | 12.5% | 2024-2026 |
| R&D Investment | $3.6 million | Annually |
| Market Penetration Target | 18% | Next 3 Years |
Strategic partnership opportunities include potential collaborations with 3-4 major healthcare technology firms to accelerate product development and market reach.
- Competitive advantages include proprietary medical technology platforms
- Advanced clinical research capabilities
- Specialized intellectual property portfolio
Viveve Medical, Inc. (VIVE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.